Vol 16, No 3 (2020)
Case report
Published online: 2020-04-16

open access

Page views 483
Article views/downloads 465
Get Citation

Connect on Social Media

Connect on Social Media

Transformation of lung adenocarcinoma treated with afatinib into small-cell carcinoma — a case report

Monika Misztal1, Magdalena Krakowska1, Mariusz Śliwa1, Piotr Potemski12
Oncol Clin Pract 2020;16(3):140-142.

Abstract

In patients with advanced lung adenocarcinoma harbouring EGFR mutations, the use of molecularly targeted therapy has significantly increased progression-free survival (PFS) and in some studies also overall survival (OS). Unfortunately, during therapy all patients develop resistance. In about half of the cases the cause of progression is the appearance of the T790M mutation of the EGFR gene. Other described resistance mechanisms are as follows: transformation into small-cell carcinoma (14%), MET amplification (5%), and PIK3CA mutations (5%). Herein we report the case of patient with disseminated lung adenocarcinoma treated with a tyrosine kinase inhibitor (afatinib), whose disease progressed after 13 months of treatment as a result of transformation into small-cell carcinoma. Despite palliative chemotherapy with cisplatin and etoposide, the patient died six months later.

Article available in PDF format

View PDF Download PDF file

References

  1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394–424.
  2. Yang JCH, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015; 16(2): 141–151.
  3. Jassem J, Krzakowski M (ed.). Nowotwory klatki piersiowej. Wydanie III. Via Medica, Gdańsk 2018.
  4. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011; 3(75): 75ra26.
  5. Li W, Ren S, Li J, et al. T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients. Lung Cancer. 2014; 84(3): 295–300.
  6. Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013; 19(8): 2240–2247.
  7. Niederst MJ, Sequist LV, Poirier JT, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun. 2015; 6: 6377.
  8. Lee JK, Lee J, Kim S, et al. Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas. J Clin Oncol. 2017; 35(26): 3065–3074.
  9. Marcoux N, Gettinger SN, O'Kane G, et al. EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes. J Clin Oncol. 2019; 37(4): 278–285.
  10. Ferrer L, Giaj Levra M, Brevet M, et al. A brief report of transformation from NSCLC to SCLC: molecular and therapeutic characteristics. J Thorac Oncol. 2019; 14(1): 130–134.